Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma

Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma

We report long-term clinical outcomes and immune responses observed from a phase 1 trial of agonist CD40 monoclonal antibody (mAb) and blocking CTLA-4 mAb in patients with metastatic melanoma. Twenty-four patients previously untreated with checkpoint blockade were enrolled. The agonistic CD40 mAb CP...

Full description

Bibliographic Details
Main Authors: David L. Bajor, Rosemarie Mick, Matthew J. Riese, Alex C. Huang, Brendan Sullivan, Lee P. Richman, Drew A. Torigian, Sangeeth M. George, Erietta Stelekati, Fang Chen, J. Joseph Melenhorst, Simon F. Lacey, Xiaowei Xu, E. John Wherry, Tara C. Gangadhar, Ravi K. Amaravadi, Lynn M. Schuchter, Robert H. Vonderheide
Format: Article
Language:English
Published: Taylor & Francis Group 2018-10-01
Series:OncoImmunology
Subjects:
cd40
ctla4
melanoma
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1468956

Internet

http://dx.doi.org/10.1080/2162402X.2018.1468956

Similar Items